Novo, Lilly fall after Trump says “the fat loss drug” will go down in price
Novo Nordisk and Eli Lilly slipped after the bell on Thursday, and continued to trade lower in the premarket session Friday, after President Trump told reporters on Thursday that “the fat loss drug” will go down in price.
Trump said GLP-1s like Novo’s Ozempic will be less than $150 out of pocket. Dr. Mehmet Oz, the Centers for Medicare & Medicaid Services administrator, interjected to say that those deals have not yet been finalized.
The Trump administration has been negotiating with drugmakers to bring down drug prices in the US. Currently, the popular weight-loss drugs made by Lilly and Novo cost between $300 and $500 a month out of pocket through the drugmakers’ direct-to-consumer platforms.
Hims & Hers, which sells compounded versions of Novo's weight loss shot, also fell on Friday. A monthly dose of Hims' compounded GLP-1 is about $200 a month, more than what Trump suggests the brand-name version could cost soon.
Q: "You mentioned a $1,300 drug?"
— The Bulwark (@BulwarkOnline) October 16, 2025
Trump: "Ya, I was referring to Ozempic, or the fat loss drug."
Q: "Those are going to be $150 out of pocket?"
Trump: "They'll be much lower."
Dr. Oz, interjecting: "We have not negotiated those yet...Ozempic has not been negotiated yet." pic.twitter.com/IlmCexTJL9
Q: "You mentioned a $1,300 drug?"
— The Bulwark (@BulwarkOnline) October 16, 2025
Trump: "Ya, I was referring to Ozempic, or the fat loss drug."
Q: "Those are going to be $150 out of pocket?"
Trump: "They'll be much lower."
Dr. Oz, interjecting: "We have not negotiated those yet...Ozempic has not been negotiated yet." pic.twitter.com/IlmCexTJL9